

Medco's Step Therapy Program for Migraine Headaches

The Step Therapy Program has been in a part of the State of Delaware's prescription plan since July 1, 2003, and ensures that a member receives the most appropriate medication while reducing the pharmacy cost for the member and the State of Delaware. Medications selected to be in the Step Therapy Program are reviewed by Medco's Independent Pharmacy and Therapeutics (P&T) Committee. This committee is made up of physicians and pharmacists who are independent of Medco.

Effective July 1, 2010, some medications used to treat migraine headaches became part of the Step Therapy Program. Members are required to try a medication classified as a "preferred or formulary" medication before obtaining a "non-preferred or non-formulary" medication. Medco mailed letters to members, at their home address, receiving Non-Preferred or Non-Formulary medications shortly prior to July 1, 2010, to advise them of this change and suggested that their physician be contacted for a new prescription.

Members receiving a Non-Preferred or Non-Formulary medication, such as Amerge, Axert, Frova, Treximet, Zomig or Zomig ZMT are required to first use a Preferred or Formulary medication, such as Maxalt, Maxalt MLT, Relpax, or Sumatriptan (generic for Imitrex). Additional information on the Step Therapy Program and the Coverage Review Process is available at <http://ben.omb.delaware.gov/script/documents/StepTherapy.pdf>

Additional information on prescription services provided by Medco is available at <http://ben.omb.delaware.gov/script/index.shtml> or Medco's website at <https://host1.medcohealth.com/medco/consumer/partner/preOpenEnroll.jsp?accessCode=SODA CTRE13852>

For further assistance contact:
Statewide Benefits Office at 1-800-489-8933 or 739-8331
Medco's Member Services at 1-800-939-2142